FIELD: chemistry; medicine.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody conjugate with a drug for treating IGF-lR-expressing cancer, as well as to a composition for treating IGF-1R-expressing cancer containing an effective amount of at least one of said drug-drug conjugate. Also disclosed is a method of treating IGF-1R-expressing cancer in a subject in need thereof, comprising using said conjugate.
EFFECT: invention enables effective treatment of IGF-lR-expressing cancer.
22 cl, 29 dwg, 16 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AND MEDICINAL AGENT CONJUGATE AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2685259C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WHICH BIND TO FLT3 PROTEINS | 2016 |
|
RU2739617C2 |
| NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| NOVEL ANTIBODY CONJUGATES AND USES THEREOF | 2014 |
|
RU2684468C2 |
| PYRROLOBENZODIAZEPINE CONJUGATES | 2017 |
|
RU2744200C2 |
| STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | 2015 |
|
RU2680238C2 |
